We observed differences in receipt of a more intensive regimen among PV carriers vs noncarriers: BRCA1/2 PV carriers with HR-positive, HER2-negative breast cancer received more intensive regimens, particularly as defined by platinum use. This evidence concerns the gene BRCA1 and breast carcinoma.